Welcome to the e-CCO Library!

P547: Distribution of mesenteric macrophage polarisation: a guide for surgical resections in Crohn’s disease?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. van der Meer*1, K. Wasmann2, J. van der Bilt3, M. Becker1, W. Bemelman2, M. Wildenberg1,4, C. Buskens2

Created: Friday, 22 February 2019, 9:41 AM
P547: Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
Year: 2022
Source: ECCO'22
Authors: Schreiber , S.(1);Galinsky , K.(2);Aubrecht , J.(2);Juarez , J.(2);Agboton , C.(3);Loftus Jr , E.V.(4);Danese , S.(5);
Created: Friday, 11 February 2022, 3:56 PM
P547: Is there an association between bariatric surgery and Crohn's disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Brcic I.*1, Todoroff A.2, Baumgartner K.2, Langner C.1, Gröchenig H.P.3

Created: Wednesday, 20 February 2019, 10:36 AM
P547: Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Barnes, E.(1)*;Zhang, X.(2);Long, M.(3);Herfarth, H.(1);Kappelman, M.(4);
Created: Friday, 14 July 2023, 11:05 AM
P547: Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: KhorshidFASGE, M.(1);Alboraie, M.(2);Abbas, W.(3);Sayed, Z.E.(3);El-Nady, M.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Fischer1, S. Mesfin1, E. Klenske1, H. Schmitt1, F. Vitali1, S. Hirschmann1, A. Ramming2, S. Zundler1, T. Rath1, S. Krebs3, F. Dörje3, W. Uter4, D. Nagore5, S. Meyer4, M.F. Neurath1, R. Atreya1

Created: Thursday, 30 January 2020, 10:12 AM
P548: Drug Survival in Patients with Inflammatory Bowel disease: An observational study
Year: 2021
Source: ECCO'21 Virtual
Authors: Kubesch, A.(1);Grimm, L.(1);Stratmann, K.(1);Knabe, M.(1);Filmann, N.(2);Sprinzl, K.(1);Hausmann, J.(1);Blumenstein, I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P548: Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn's disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Atreya, R.(1)*;Irving, P.(2);Fujiya, M.(3);Colombel, J.F.(4);Danese, S.(5);Peyrin-Biroulet, L.(6);Bessissow, T.(7);Panaccione, R.(8);D'Haens, G.(9);van Haaren, S.(10);Neimark, E.(11);Zambrano, J.(12);Zhang, Y.(13);Kligys, K.(10);Ferrante, M.(14);
Created: Friday, 14 July 2023, 11:05 AM
P548: External validation and consistency in time of patient segmentation based on disease acceptance and perceived control in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Van Erp, L.W.(1);Thomas, P.W.A.(2);Groenen, M.J.M.(1);Bloem, S.(3);Russel, M.G.V.M.(4);Römkens, T.E.H.(5);Wahab, P.J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P548: Hepatitis B virus reactivation in hepatitis B virus infected patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lee J.M.*1, Lee K.-M.1, Kim H.-S.2, Ye B.D.3, Park S.J.4, Park S.H.3, Im J.P.5, Jang B.I.6, Kim D.B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P548: Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Ferrante*, B. Verstockt, L. Gijbels, G. Van Assche, S. Vermeire

Created: Thursday, 21 February 2019, 9:14 AM
P548: Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. S. Dulai*1, Z. Huang2, Y. Wan2, M. Luo2

Created: Friday, 22 February 2019, 9:41 AM
P549 A virtual clinic enhances the quality use of anti-TNF dose intensification and rates of treatment success using a treat-to-target approach compared with standard outpatient care in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Srinivasan1,2,3, D.R. van Langenberg1,3, R. Little4, M.P. Sparrow3,4, P. De Cruz2,5, M.G. Ward3,4

Created: Thursday, 30 January 2020, 10:12 AM
P549: Changing Lanes: Switching Therapies in Inflammatory Bowel Disease, An Observational Study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Mc Gettigan, N.(1);Leung, E.(2);Harhen, A.(2);Anderson, E.(2);McMahon, S.(2);Walshe, M.(2);Keohane, J.(2);Sengupta, S.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P549: Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Feagan B.G.*1, Gasink C.2, Pollack P.2, Jacobstein D.2, Gao L.-L.2, Johanns J.2, Miao Y.2, Targan S.3, Ghosh S.4

Created: Wednesday, 20 February 2019, 10:36 AM
P549: One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dalal, R.(1)*;Sharma, P.(2);Bains, K.(3);Pruce, J.(1);Allegretti, J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P549: Oxidative stress and antioxidant capacity biomarkers in adults and children with IBD: current update from OxIBDiet trial
Year: 2022
Source: ECCO'22
Authors: Quattrini, S.(1);Gatti, S.(1);Palpacelli, A.(1);Mattioli, S.(1);Cianfruglia, L.(2);Galezzi, T.(1);Monachesi, C.(1);Quatraccioni, C.(3);Catassi, G.(4);Di Sario, A.(5);Armeni, T.(2);Catassi, C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P549: Systemic cytomegalovirus infection is a relevant factor affecting short- and long-term outcomes of patients with acute severe ulcerative colitis: An 11-year experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

F.S. Macaluso1*, S. Compagnoni1, S. Renna1, S. Maisano1, A. Casà1, G. Solina2, A.G. Rizzo3, F. La Seta4, M. Ventimiglia1, A. Orlando1, M. Cottone1

Created: Thursday, 21 February 2019, 9:14 AM
P549: Vitamin D deficiency as a part of extraintestinal manifestations in IBD Patients: a single-centre experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Georgieva*1, A. Atanassova1, D. Gerova2, M. Todorova2

Created: Friday, 22 February 2019, 9:41 AM
P550 Long-term effectiveness of anti-TNF agents in symptomatic stricturing Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Rodríguez-Lago1, J. Del Hoyo2, M.J. Casanova3, A. Fernández-Clotet4, M.J. García5, R. Ferreiro-Iglesias6, M. Piqueras7, C. Suárez8, A. López-García9, M. Arroyo10, M. Sierra11, P. Delgado-Guillena12, I. Guerra13, O. Merino14, L. Arranz15, J. Llaó16, R. Plaza17, G. Molina18, P. Torres19, P. Pérez-Galindo20, C. Herrera-deGuise21, E. Armesto22, F. Mesonero23, U. Aguirre24, J.P. Gisbert25, EFATECS study group from GETECCU

Created: Thursday, 30 January 2020, 10:12 AM